Chronic Obstructive Pulmonary Disease (COPD)
Conditions
Keywords
multiple inhaled, NVA237, COPD
Brief summary
This study will evaluate the pharmacokinetics, pharmacodynamics and safety of multiple doses of the NVA237 in mild and moderate COPD patients .
Interventions
DRUGNVA237
DRUGPlacebo
Sponsors
Novartis
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Male and/or female patients aged from 40-75 years of age with mild to moderate COPD. * Diagnosis of mild/moderate COPD, according to the GOLD guidelines. * Bronchodilatory response to ipratropium at screening * Current or ex-smokers with a smoking history of \>10 pack-years. Ten pack-years is defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years etc. * Female patients must have been surgically sterilized at least 6 months prior to screening or: Postmenopausal women must have no regular menstrual bleeding for at least 1 year prior to inclusion. * Lab and post-bronchodilator values within a certain range. * Body mass index (BMI) must be within the range of 18 to 32 kg/m2.
Exclusion criteria
* Any significant medical condition that in the opinion of the Investigator may compromise patient safety, patient compliance, interfere with evaluations, or preclude completion of the trial. * Any medical condition that may make spirometry unsafe * History of glaucoma, symptomatic prostatism or urinary retention. * Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations and for any other limitation of participation based on local regulations. Previous participation in a study with either the investigational or comparator drugs does not exclude a patient from participation in this study. * Donation or loss of 400 ml or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation. * Significant illness (other than respiratory illness) within the two weeks prior to dosing. * Clinically significant ECG abnormalities indicative of an unstable underlying cardiac problem, e.g. recent myocardial infarction, 2nd/3rd degree heart block, or a family history grandparents, parents and siblings of a prolonged QT-interval syndrome. * History of clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or drugs similar to the study drug. * History of immunocompromise, including a positive HIV (ELISA and Western blot) test result. * A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result. * History of drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the screening or baseline evaluations. * Patients who are unable to demonstrate appropriate use of the Concept 1 device at screening Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetics (PK) of NVA237 following single and repeated once-daily inhaled NVA237 doses | — |
Secondary
| Measure | Time frame |
|---|---|
| -Pharmacodynamics (PD) and PK/PD relationships of NVA237 following single and repeated once-daily inhaled NVA237 doses -Safety and tolerability of NVA237 following single and repeated once-daily inhaled NVA237 doses | — |
Countries
Denmark, Germany
Outcome results
None listed